On Wednesday, the Food and Drug Administration approved the Maestro system, a surgically implanted device manufactured by EnteroMedics that can help treat obesity in adults. The device, the first of its kind, generates an electrical pulse that prevents nerve signals from the brain from getting to the stomach. Basically it stops someone from feeling hungry. […]
Novel obesity treatment company EnteroMedics (NASDAQ:ETRM) that has survived a close brush with disaster recorded revenue for the first time since it was incorporated nearly eight years ago. On Tuesday, the company reported revenue of about $123,000 in the first quarter of the year that were garnered from the sale of its implantable neuromodulation system — Maestro […]
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Analyst Debbie Wang of Morningstar remembers that day in October 2009 when obesity treatment firm EnteroMedics (NASDAQ:ETRM) held a conference call to explain that its highly anticipated Maestro device had failed to meet a goal in a clinical trial. “Honestly, the CEO sounded like he was shell-shocked,” she recalled. “He sounded like he couldn’t believe […]
Obese Australians will be among the first in the world to use a Minnesota company’s therapy that uses an implantable neurostimulator to achieve weight loss. EnteroMedics (NASDAQ:ETRM) announced this week that it has shipped its first commercially available Maestro Rechargeable System to its distribution partner in Australia. The Maestro system delivers VBLOC (vagus nerve-blocking therapy) designed to […]
EnteroMedics Inc. (NASDAQ:ETRM) closed its $29.8 million public offering of 17 million shares of common stock and 17 million corresponding warrants. The St. Paul, Minnesota-based anti-obesity device maker plans to use the $27.6 million it netted from the offering to support the regulatory approval of its neuroblocking Maestro RC system. The stock went for aggregate […]
Hoping to push its groundbreaking obesity-fighting device across the proverbial finish line, EnteroMedics Inc. (NASDAQ:ETRM) is selling 12 million new shares to the public
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
Minnesota medical device and biotech companies won about $24 million in tax credits and grants from the Qualified Therapeutic Discovery program. The $1 billion initiative born from federal healthcare reform law seeks to boost companies working on therapies that save money.
Let’s do it again. EnteroMedics Inc., based in Roseville, Minnesota, said Monday that the Food and Drug Administration has approved a new clinical trial for its Maestro anti-obesity device that uses electricity to suppress hunger. The news represents a major victory for EnteroMedics whose previous study ended in failure. Last October, initial results from the […]
Merck & Co. is no longer a drug company. Or at least that’s one of its top executives told the Innovations in Diabetes Summit in St. Louis Park, Minnesota Wednesday. Now before you start shorting Merck stock, the company, a longtime stalwart of Big Pharma, is still very much in the business of making pharmaceuticals. […]
CVRx Inc. in Plymouth, Minn. said Monday that hypertension patients using its Rheos stimulation device reported a sharp drop in blood pressure after four years. In a study presented to the European Society of Hypertension meeting, the company said patients’ average systolic blood pressure dropped 27 percent to 140 mmHg (millimeters of mercury) from 193 […]
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Ernie Andberg has a little more free time on his hands these days. The long-time “emerging medical device companies” equity analyst for Feltl & Co. in Minneapolis has not seen a lot of companies emerging lately. In fact, they’ve been disappearing all together. Case in point: Medtronic Inc.’s (NYSE: MDT) deal last week to acquire […]
Someday, in the not-so-distant future, EnteroMedics Inc. officials might look back at late 2009 and laugh. Or cry. That ultimately depends on whether the Food and Drug Administration ultimately approves or rejects the company’s groundbreaking Maestro device. Approval means enormous financial success, the only implantable neurostimulation device in the United States designed to treat obesity. […]
Patients will measure their vital signs such as blood pressure, pulse and weight, and respond to questions related to their diseases on a daily basis. A clinical care team will review the data, and will be able to use videoconferencing to further evaluate the patients.
EnteroMedics and Leptos are both developing a device that uses electricity to treat obesity. But that's where the similarities end, EnteroMedics CEO Mark Knudson told me in a quick phone call.
Leptos had raised at least $10 million from big venture capital firms like Thomas, McNerney Partners in Minneapolis, Technology Partners in Palo Alto, Calif. and Spray Ventures in Newton, Mass. Like EnteroMedics Inc. in Roseville, the company was developing a device that used electricity to manipulate signals between the brain and stomach.